DK3700529T3 - Ny kombination af aktive midler til behandling af progressive fibroserende interstitielle lungesygdomme (pf-ild) - Google Patents

Ny kombination af aktive midler til behandling af progressive fibroserende interstitielle lungesygdomme (pf-ild)

Info

Publication number
DK3700529T3
DK3700529T3 DK18785961.6T DK18785961T DK3700529T3 DK 3700529 T3 DK3700529 T3 DK 3700529T3 DK 18785961 T DK18785961 T DK 18785961T DK 3700529 T3 DK3700529 T3 DK 3700529T3
Authority
DK
Denmark
Prior art keywords
fibrosating
ild
progressive
treatment
active agents
Prior art date
Application number
DK18785961.6T
Other languages
English (en)
Inventor
Franziska Elena Herrmann
Peter Nickolaus
Stefan Ludwig Michael Wollin
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Application granted granted Critical
Publication of DK3700529T3 publication Critical patent/DK3700529T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK18785961.6T 2017-10-23 2018-10-12 Ny kombination af aktive midler til behandling af progressive fibroserende interstitielle lungesygdomme (pf-ild) DK3700529T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17197719 2017-10-23
PCT/EP2018/077952 WO2019081235A1 (en) 2017-10-23 2018-10-12 NEW ASSOCIATION OF ACTIVE AGENTS FOR THE TREATMENT OF PROGRESSIVE FIBROSANT INTERSTITIAL PNEUMOPATHY (PF-ILD)

Publications (1)

Publication Number Publication Date
DK3700529T3 true DK3700529T3 (da) 2025-09-22

Family

ID=60162029

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18785961.6T DK3700529T3 (da) 2017-10-23 2018-10-12 Ny kombination af aktive midler til behandling af progressive fibroserende interstitielle lungesygdomme (pf-ild)

Country Status (26)

Country Link
US (4) US11406638B2 (da)
EP (2) EP4603094A2 (da)
JP (1) JP7196169B2 (da)
KR (2) KR20250172732A (da)
CN (1) CN111278442B (da)
AU (2) AU2018357775B2 (da)
BR (1) BR112020003973A2 (da)
CA (1) CA3079299A1 (da)
CL (1) CL2020000627A1 (da)
DK (1) DK3700529T3 (da)
EA (1) EA202090977A1 (da)
ES (1) ES3041129T3 (da)
FI (1) FI3700529T3 (da)
HR (1) HRP20251042T1 (da)
HU (1) HUE072914T2 (da)
IL (2) IL273169B2 (da)
LT (1) LT3700529T (da)
MA (1) MA50441A (da)
MX (1) MX2020004173A (da)
PH (1) PH12020550452A1 (da)
PL (1) PL3700529T3 (da)
PT (1) PT3700529T (da)
RS (1) RS67241B1 (da)
SI (1) SI3700529T1 (da)
TW (1) TWI700088B (da)
WO (1) WO2019081235A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230201144A1 (en) * 2020-05-29 2023-06-29 Novomedix, Llc Biarylsulfonamides and pharmaceutical compositions thereof, and their use for treating fibrotic lung disease
CN113116904B (zh) * 2021-03-23 2022-11-29 深圳市泰力生物医药有限公司 尼达尼布-甘草次酸复方制剂和药物复方制剂及在制备治疗肺纤维化药物中的应用
EP4494701A3 (en) * 2021-12-09 2025-04-02 Boehringer Ingelheim International GmbH New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
EP4426307B1 (en) * 2021-12-09 2025-07-02 Boehringer Ingelheim International GmbH New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases
IL317209A (en) * 2022-05-28 2025-01-01 Avalyn Pharma Inc Nintedanib and combined dry powder preparations Nintedanib and uses
US20250326765A1 (en) * 2022-06-02 2025-10-23 Xizang Haisco Pharmaceutical Co., Ltd. Pde4b inhibitor and use thereof
WO2023241683A1 (zh) * 2022-06-16 2023-12-21 武汉人福创新药物研发中心有限公司 作为pde4b抑制剂的含氮杂环类化合物
IL318673A (en) * 2022-08-09 2025-03-01 Xizang Haisco Pharmaceutical Co Ltd PDE4B inhibitor and its use
WO2024068386A1 (en) 2022-09-28 2024-04-04 Boehringer Ingelheim International Gmbh Use of biomarkers in the treatment of fibrotic conditions with a pde4b-inhibitor
KR20240159339A (ko) * 2023-04-28 2024-11-05 한국원자력의학원 폐섬유화 예방 또는 치료를 위한 다코미티닙 및 닌테다닙의 병용 요법
KR20240159340A (ko) * 2023-04-28 2024-11-05 한국원자력의학원 폐섬유화 예방 또는 치료를 위한 펙시다티닙 및 닌테다닙의 병용 요법
WO2025092985A1 (zh) * 2023-11-03 2025-05-08 合肥医工医药股份有限公司 磷酸二酯酶4b抑制剂及其制备方法与用途
WO2026046267A1 (zh) * 2024-08-28 2026-03-05 石药集团中奇制药技术（石家庄）有限公司 二氢噻吩并嘧啶衍生物的结晶形式及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1049411A (en) 1972-12-18 1979-02-27 Affiliated Medical Research N-substituted pyridone and general method for preparing pyridones
CN1046939C (zh) 1993-07-02 1999-12-01 比克·古尔顿·劳姆贝尔格化学公司 氟烷氧基取代的苯甲酰胺类及其制备方法和应用
US6020358A (en) 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US6762180B1 (en) 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
DE10233500A1 (de) 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
DE102004057645A1 (de) 2004-11-29 2006-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen
DE102004057594A1 (de) 2004-11-29 2006-06-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substitueirte Pteridine zur Behandlung von entzündlichen Erkrankungen
DE102004057618A1 (de) 2004-11-29 2006-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen
DE102004057595A1 (de) 2004-11-29 2006-06-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen
PE20060777A1 (es) * 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
CN101163706A (zh) 2005-04-21 2008-04-16 贝林格尔·英格海姆国际有限公司 用于治疗炎性疾病的二氢噻吩并嘧啶
EP1847543A1 (de) 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
EP1870400A1 (en) 2006-06-08 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG Salts and crystalline salt forms of an 2-indolinone derivative
JP5341899B2 (ja) 2007-10-19 2013-11-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ヘテロ環置換ピペラジノ−ジヒドロチエノピリミジン
ES2524910T3 (es) 2007-10-19 2014-12-15 Boehringer Ingelheim International Gmbh Piperidino-dihidrotienopirimidinas sustituidas
UA107560C2 (uk) 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
HRP20180709T1 (hr) 2008-06-06 2018-06-15 Boehringer Ingelheim International Gmbh Farmaceutski dozni oblik kapsule koji obuhvaća suspenzijsku formulaciju derivata indolinona
US20130059866A1 (en) * 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
US9802954B2 (en) * 2011-08-24 2017-10-31 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
WO2014124860A1 (en) * 2013-02-14 2014-08-21 Boehringer Ingelheim International Gmbh Specific pde4b-inhibitors for the treatment of diabetes mellitus
CN106535896B (zh) * 2015-04-27 2019-06-21 江苏恒瑞医药股份有限公司 蛋白激酶抑制剂在制备治疗纤维化疾病的药物中的用途
CZ308695B6 (cs) 2015-07-29 2021-03-03 Zentiva, K.S. Způsob přípravy methyl (Z)-3[[4-[methyl[2-(4-methyl-1piperazinyl)acetyl]amino]fenyl]amino]fenylmethylen)-oxindol-6karboxylátu (intedanibu, nintedanibu)

Also Published As

Publication number Publication date
CN111278442B (zh) 2023-06-06
EA202090977A1 (ru) 2020-09-04
JP2021500362A (ja) 2021-01-07
CN111278442A (zh) 2020-06-12
IL273169A (en) 2020-04-30
IL273169B2 (en) 2024-05-01
PL3700529T3 (pl) 2025-12-22
MA50441A (fr) 2020-09-02
IL309150B1 (en) 2024-11-01
PH12020550452A1 (en) 2021-03-15
TWI700088B (zh) 2020-08-01
US20250241919A1 (en) 2025-07-31
IL273169B1 (en) 2024-01-01
KR102893133B1 (ko) 2025-12-02
ES3041129T3 (en) 2025-11-07
TW201929858A (zh) 2019-08-01
CL2020000627A1 (es) 2020-08-21
IL309150B2 (en) 2025-03-01
US11813266B2 (en) 2023-11-14
AU2018357775B2 (en) 2024-02-15
KR20200075864A (ko) 2020-06-26
AU2024203045B2 (en) 2026-02-19
BR112020003973A2 (pt) 2020-09-01
NZ762200A (en) 2024-10-25
FI3700529T3 (fi) 2025-09-18
RS67241B1 (sr) 2025-10-31
MX2020004173A (es) 2020-08-03
EP4603094A2 (en) 2025-08-20
HUE072914T2 (hu) 2025-12-28
US20220378793A1 (en) 2022-12-01
KR20250172732A (ko) 2025-12-09
US20230405010A1 (en) 2023-12-21
EP3700529A1 (en) 2020-09-02
SI3700529T1 (sl) 2025-10-30
AU2024203045A1 (en) 2024-05-23
AU2018357775A1 (en) 2020-03-19
US20190134043A1 (en) 2019-05-09
WO2019081235A1 (en) 2019-05-02
LT3700529T (lt) 2025-10-10
EP3700529B1 (en) 2025-07-09
PT3700529T (pt) 2025-09-17
US12233068B2 (en) 2025-02-25
JP7196169B2 (ja) 2022-12-26
CA3079299A1 (en) 2019-05-02
US11406638B2 (en) 2022-08-09
IL309150A (en) 2024-02-01
HRP20251042T1 (hr) 2025-10-24

Similar Documents

Publication Publication Date Title
DK3700529T3 (da) Ny kombination af aktive midler til behandling af progressive fibroserende interstitielle lungesygdomme (pf-ild)
DK3728271T3 (da) Makrocykliske forbindelser til behandling af sygdomme
PL3600309T3 (pl) Skojarzenia terapeutyczne do leczenia chorób wątroby
LT3416631T (lt) Terapiniai agentai, skirti neurodegeneracinių ligų gydymui
DK3347030T3 (da) Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme
DK3326641T3 (da) Rna-holdig sammensætning til behandling af tumorsygdomme
EP3263132C0 (en) COMPOSITION FOR THE TREATMENT OF DISEASES ASSOCIATED WITH IL-6
HUE057795T2 (hu) Adenoasszociált vírus terápiás szerek központi idegrendszerbe történõ bejuttatására
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3240538T3 (da) Anvendelse af masitinib til behandling af en underpopulation af patienter med amyotrofisk lateralsklerose
EP3636305A4 (en) MEDICAL NEBULIZER
DK3609529T3 (da) Rna til behandling af autoimmune sygdomme
EP3723692A4 (en) MEDICAL ASSISTANT
HUE060496T2 (hu) Terápiás vegyületek és készítmények szociális zavarok és szerhasználati zavarok kezelésére
IL281244A (en) Combination therapy for the treatment of liver disease
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
EP3612133A4 (en) Implantable scaffolds for treatment of sinusitis
EP3927328A4 (en) INHALABLE THERAPEUTIC AGENT
HUE061741T2 (hu) Maszk szemszárazság kezelésére
IL282120A (en) Buprenorphine to treat respiratory depression
IL280968A (en) Combination therapy
EP3577224A4 (en) NEW TREATMENT FOR NEAT1-ASSOCIATED ILLNESS
IL259381B (en) Mirabegron for the treatment of retinal diseases
IL288237A (en) Combination therapy
IL288793A (en) Compounds for treating respiratory disease